The use of PARP inhibitors, particularly in BRCA1- and BRCA2-mutant ovarian cancers, has revolutionized the management of these patients and has been one of the most successful achievements in the last decade in the field. The gene discussed is BRCA2; the disease is ovarian carcinoma.